First Patient In Boston’s ZERO AF Blazer® Open-Irrigated Temperature Ablation Catheter Trial

The first patient has been treated in the Boston Scientific’s ZERO AF clinical trial to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Temperature Ablation Catheter in patients with symptomatic, drug refractory paroxysmal atrial fibrillation. This international, multi-center study will include up to 472 patients at 33 sites in the United States, Europe and Asia-Pacific.